ClinicalTrials.gg
TerminatedNCT04401475Updated Oct 28, 2026

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

A Phase 2/3 interventional study of SOC plus 15mg/kg EB05 IV and SOC plus Placebo IV in COVID-19 and ARDS, sponsored by Edesa Biotech Inc.. Terminated at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Edesa Biotech Inc. · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Edesa has made the decision to terminate this study solely for business reasons. The study termination was not related to any safety concerns.

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.
Updated Sep 30, 2026Now TerminatedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
278
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 289 studies in COVID-19 with a site in Canada — 24 open to participants now, 37 under way, 9 of them phase 3. COVID-19 · Canada.

Enrollment
70th of 200
278 · median 120
Started
2020
with 120 others
Phase 2/3
16 of 289
none open now
Registered
55th of 289
by date

Among the 289 studies in COVID-19 with a site in Canada, this one is the 70th largest by enrollment of the 200 interventional ones that give a count, is one of 121 that started in 2020, is one of 16 in phase 2/3, and was the 55th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

24 of the 289 studies in COVID-19 with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in COVID-19 with a site in Canada, or all of them as a file.
02

Study summary

COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response. This in turn stimulates a pro-inflammatory cascade ("cytokine storm") as well as emergency myelopoiesis.

This proinflammatory cascade is activated when viral-mediated cell damage occurs in the lungs, resulting in the release of damage-signaling alarmin molecules such as S100A8/A9 (Calprotectin), HMGB1, Resistin, and oxidized phospholipids. These damage-associated molecular patterns (DAMPs) are recognized by the pattern recognition receptor Toll-Like Receptor 4 (TLR4) found on macrophages, dendritic cells and other innate immune cells and result in additional release of pro-inflammatory molecules. Several recent studies have shown that S100A8/A9 serum levels in hospitalized COVID-19 patients positively correlate with both neutrophil count and disease severity. Taken together the DAMP-TLR4 interaction forms a central axis in the innate immune system and is a key driver of the pathological inflammation observed in COVID-19. We hypothesis that targeting the initial step in the signalling pathways of these DAMPs in innate immunity offers the best hope for controlling the exaggerated host response to SARS-CoV-2 infection.

EB05 has demonstrated safety in two clinical studies (>120 patients) and was able to block LPS-induced (TLR4 agonist) IL-6 release in humans. Given, this extensive body of evidence we believe EB05 could ameliorate ARDS due to COVID-19, significantly reducing ventilation rates and mortality.

03

Conditions studied

  • COVID-19
  • ARDS

Browse trials for

Keywords

  • TLR4
  • ARDS
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥18 years of age at the time of consent.
  2. Laboratory-confirmed diagnosis of COVID-19.
  3. Hospitalized for COVID-19 related respiratory disease.
  4. Patient belongs to one of the following two categories in the nine-point COVID-19 severity scale:

    1. Hospitalized, requiring intubation and mechanical ventilation - Level 6 of the nine-point COVID-19 severity scale.
    2. Hospitalized and intubated with additional organ support - pressors, RRT, ECMO - Level 7 of the nine-point COVID-19 severity scale.
  5. For women of involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use (consistent with local regulations) during the study period.
  6. Signed obtained by any patient capable of giving consent, or, when the patient is not capable of giving consent, from his or her legal/authorized representatives.

Exclusion criteria

Exclusion Criteria:

  1. The subject is a female who is breastfeeding or pregnant.
  2. Known to EB05 or its .
  3. In the opinion of the investigator, death is imminent and inevitable or patient will be discharged within the next 48 - 72 hours, irrespective of the provision of treatment.
  4. Experiencing cardiac arrest while hospitalized with COVID-19.
  5. Active participation in other immunomodulator or drug clinical trials.

    a. Participation in COVID-19 antiviral, anticoagulant and convalescent plasma trials may be permitted; however, the decision to enroll a patient who is participating in other clinical trials will be dealt with on a case-by-case basis.

  6. Treatment with immunomodulator or immunosuppressant drugs, including but not limited to TNF inhibitors and anti-IL-1 agents within 5 half-lives or 30 days (whichever is longer) before randomization. Except for the following, which are permitted:

    1. Treatment with immunomodulator, or immunosuppressant drugs, such as , as part of SOC for COVID-19
    2. Transplant patients
  7. Known other clinical conditions that contraindicate EB05 and cannot be treated or solved according to the judgment of the clinician.
  8. Patient has been intubated or mechanically ventilated for more than 72 hours prior to administration of the product.
  9. Patient has been intubated and then extubated during the current hospitalization prior to administration of the investigational product.
  10. Patient has experienced meaningful clinical improvement in the severity of disease prior to administration of the investigational product.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
278 participants (actual)

Study arms

  • Experimental
    Stage 1

    Stage 1 (Phase II Study) For 80% power (β = 0.20), at a significance level of 5% (α =0.05) and a 1:1 randomization ratio, a total of 316 (EB05: 158, SOC: 158) evaluable patients will be required. Allowing for 20% attrition a total of 396 patients will be recruited.

    Biological: SOC plus 15mg/kg EB05 IV · Other: SOC plus Placebo IV

  • Experimental
    Stage 2

    Stage 2 (Phase III Study) For a 1:1 ratio of patients treated with EB05 vs. Placebo, a cumulative one-sided alpha of 2.5% and 90% power, to detect an Odds Ratio of 2.00, a total of 586 evaluable patients will be required for Stage 2 (Phase III study). 293 of these will be treated with EB05 + SOC and 293 treated with Placebo + SOC. Allowing for 10% attrition, a total of 644 patients will be enrolled in this Stage.

    Biological: SOC plus 15mg/kg EB05 IV · Other: SOC plus Placebo IV

Interventions

  • BiologicalSOC plus 15mg/kg EB05 IV

    Standard of care plus single IV infusion of 15mg/kg of EB05.

  • OtherSOC plus Placebo IV

    Standard of care plus a single IV infusion of placebo.

06

What researchers measure

Primary outcomes

  1. Mortality rate at Day 28 from IP administration. (Phase 2 and 3)

    For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation.

    Time frame: 28 days

Secondary outcomes

  1. Proportion of patients with clinical improvement at Day 28 (Phase 2 and 3)

    The proportion of patients with clinical improvement, defined as a decrease of two points or more on the World Health Organization (WHO) 9 - point ordinal scale at Day 28 from IP administration. The severity of COVID-19 disease is classified according to the WHO 9-point ordinal scale. The minimum value of 0 is associated with an "uninfected" stage wherein no clinical or virological evidence of infection is present. The maximum value of 8 is associated with death. A higher score reflects a worse outcome.

    Time frame: 28 days

  2. Proportion of patients with clinical improvement at Day 60 (Phase 2)

    The proportion of patients with clinical improvement, defined as a decrease of two points or more on the World Health Organization (WHO) 9 - point ordinal scale at Day 60 from IP administration. The severity of COVID-19 disease is classified according to the WHO 9-point ordinal scale. The minimum value of 0 is associated with an "uninfected" stage wherein no clinical or virological evidence of infection is present. The maximum value of 8 is associated with death. A higher score reflects a worse outcome.

    Time frame: 60 days

  3. Mortality rate at Day 60 from IP adminstration (Phase 2 and 3)

    The mortality rate at Day 60 from IP administration.

    Time frame: 60 days

Other outcomes

  1. Number of treatment-emergent adverse events (TEAEs) and serious TEAEs.

    Safety Endpoint: Number of treatment-emergent adverse events (TEAEs) and serious TEAEs.

    Time frame: 28 and 60 days

07

Study locations

20 sites
  • UCSF Fresno
    Fresno, California 93701, United States
  • St. Jude Medical Center/ Providence
    Fullerton, California 92835, United States
  • University of Miami Hospital
    Coral Gables, Florida 33146, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Wayne State University
    Detroit, Michigan 48202, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • West Virginia University Medicine Heart & Vascular Institute
    Morgantown, West Virginia 26506-6224, United States
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Vancouver Coastal Health
    Vancouver, British Columbia V5K 1Z9, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • William Osler Health System
    Brampton, Ontario L6R 3J7, Canada
  • Markham Stouffville Hospital
    Markham, Ontario L3P 7P3, Canada
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • Lakeridge Health
    Oshawa, Ontario L1G 2B9, Canada
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1Y 4E9, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • CISS Monteregie-Centre
    Greenfield Park, Quebec J4V 2H2, Canada
  • Hôpital Maisonneuve Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Hôpital Régional de Rimouski
    Rimouski, Quebec G5L 5T1, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2020 to primary completion in Jul 2024, 43 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2024 → Jul 2024 and completion Dec 2024 → Jul 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2020
First posted
May 26, 2020
StartActual
Nov 25, 2020
Primary completionActual
Jul 22, 2024was Dec 2024
CompletionActual
Jul 22, 2024was Dec 2024
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated Edesa has made the decision to terminate this study solely for business reasons. The study termination was not related to any safety concerns.
changed Sep 30, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Canada)
  • Hôpital Maisonneuve Rosemont · Montreal, Canada
  • McGill University Health Centre · Montreal, Canada
Show 2 removed
  • Hôpital Maisonneuve Rosemont · Montréal, Canada
  • McGill University Health Centre · Montréal, Canada
Sep 30, 2026
Primary completion
Dec 2024→Jul 22, 2024 (actual)
Sep 30, 2026
Study completion
Dec 2024→Jul 22, 2024 (actual)
Sep 30, 2026
Enrollment
644 (estimated)→278 (actual)
Sep 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMortality rate at Day 28 from IP administration. (Phase 2 and 3)Time frame: 28 days
Sep 30, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedProportion of patients with clinical improvement at Day 28 (Phase 2 and 3)Time frame: 28 days
  • EditedProportion of patients with clinical improvement at Day 60 (Phase 2)Time frame: 60 days
  • EditedMortality rate at Day 60 from IP adminstration (Phase 2 and 3)Time frame: 60 days
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Suspended→Terminated
    Why stopped Edesa has made the decision to terminate this study solely for business reasons. The study termination was not related to any safety concerns.
    2 sites added, 2 sites removed
    Show 2 added (2 Canada)
    • Hôpital Maisonneuve Rosemont · Montreal, Canada
    • McGill University Health Centre · Montreal, Canada
    Show 2 removed
    • Hôpital Maisonneuve Rosemont · Montréal, Canada
    • McGill University Health Centre · Montréal, Canada
    Primary completion Dec 2024→Jul 22, 2024 (now actual)
    Study completion Dec 2024→Jul 22, 2024 (now actual)
    Enrollment 644 (estimated)→278 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMortality rate at Day 28 from IP administration. (Phase 2 and 3)Time frame: 28 days
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedProportion of patients with clinical improvement at Day 28 (Phase 2 and 3)Time frame: 28 days
    • EditedProportion of patients with clinical improvement at Day 60 (Phase 2)Time frame: 60 days
    • EditedMortality rate at Day 60 from IP adminstration (Phase 2 and 3)Time frame: 60 days
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04401475
Lead sponsor
Edesa Biotech Inc.
Collaborators
JSS Medical Research Inc.
Responsible party
Sponsor
First posted
May 26, 2020
Start date
Nov 25, 2020
Primary completion
Jul 22, 2024
Completion
Jul 22, 2024
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion